The components of the apoptotic program are targets for anticancer therapy. Bcl-2 protein
inhibits apoptosis and confers resistance to treatment with traditional cytotoxic …

The immune system, and in particular T cells, can be harnessed to treat cancer. Several
bispecific T cell engaging antibodies of the BiTE® format are in early or late-stage clinical …

A unique mRNA produced in leukemic cells from at (15; 17) acute promyelocytic leukemia
(APL) patient encodes a fusion protein between the retinoic acid receptor a (RARa) and a …

Abstract Background and Methods. Patients with acute promyelocytic leukemia have a
characteristic (15; 17) translocation, with a breakpoint on chromosome 17 in the region of …

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide
hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell …

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment
Refractory Cutaneous T-Cell Lym Page 1 Phase IIB Multicenter Trial of Vorinostat in Patients …

PURPOSE: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with
relapsed acute promyelocytic leukemia (APL). PATIENTS AND METHODS: Forty patients …

▪ Objective: To describe a novel complication of therapy with all-trans retinoic acid in patients
with acute promyelocytic leukemia.▪ Design: Case series.▪ Setting: Comprehensive cancer …

The goal of this phase II multicenter clinical trial was to evaluate a new intensive
chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to …

1. Introduction. The development of high-speed digital computers1 has made feasible the
numerical solution by iterative methods of some partial differential equations. The …